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Introduction
The sarco/endoplasmic reticulum (SR/ER) calcium (Ca2+)-ATPase (SERCA) pump is a key
regulator of intracellular Ca2+ homeostasis and subsequently essential for cell survival and function
[1,2]. Neurons are no exception to this; intricate pathways involving SERCA-mediated
Ca2+ signaling are implicated in brain pathophysiology. Several studies have indicated that
dysregulation of SERCA pumps may be involved in the molecular mechanisms underlying
debilitating brain diseases including Alzheimer’s and Parkinson’s diseases, schizophrenia, bipolar
disorder, ischemia and alcoholism [1-3]. Thus, this family of P-type ATPases comprises an
emerging molecular target for developing efficient pharmacotherapies. Interestingly, preclinical
studies in rodents suggest that chronic pharmacological activation of SERCA2 by the quinoline
derivative CDN1163 comprises a potential pharmacotherapeutic target in Alzheimer’s and
Parkinson’s diseases [4-6]. As little is known about the behavioral and neurochemical
consequences of CDN1163 administration, in this study we investigated the potential effects of
both acute and chronic pharmacological SERCA stimulation on the behavior and monoaminergic
neurotransmission of naïve C57BL/6J mice of both sexes [7].
Methodology
Results- Conclusions
• Acute treatment with both the 10mg/kg and the 20mg/kg doses of CDN1163 did not induce any
behavioral effects in male and female mice as assessed by: the distance travelled in the OF
(Fig. 1a-b); the time spent in the center of the OF arena (Fig. 1c); the time spent grooming in
the splash test (Fig. 1d); the time spent in the light compartment of the light/dark box (Fig. 1e);
or immobility duration in the FST (Fig. 1f-g).
• Chronic CDN1163 treatment did not affect locomotor activity (Fig. 2a-b) but induced an
anxiogenic effect as the 10mg/kg dose significantly decreased the time mice spent in the center
of the OF arena (Fig. 2c).
• Chronic CDN1163 treatment did not affect grooming behavior in the splash test (Fig. 2d), or the
time mice spent in the light compartment of the dark/light box (Fig. 2e).
• Mice chronically treated with both doses of CDN1163 displayed increased immobility duration in
the FST, indicating a depressive-like effect (Fig. 2f-g).
• Chronic CDN1163 administration tended to increase NA levels in the PFC the HIPP and the
STR in a sex-specific manner as NA levels increased in a dose-dependent manner only in
males (Fig 3a-c).
• Chronic administration of the 20mg/kg CDN1163 dose induced an increase in 5-HT levels in
male mice, whereas female mice presented a decrease in 5-HT content, suggesting that
pharmacological SERCA activation exerts persistent sex-specific effects on the striatal
serotonergic status (Fig. 3d).
Fig. 1: Acute CDN1163 administration does not affect mouse behavior.
Fig. 2: Chronic CDN1163 administration induces anxiogenic and depressive-like effects in mice.
Fig. 3: Chronic treatment with CDN1163 induces sex- and dose-dependent noradrenergic and serotonergic neurochemical effects.
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